Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
30 Agosto 2023 - 8:30AM
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage
immuno-oncology company focused on the discovery and development of
next-generation therapeutics for cancer patients, today announced
that Company management will participate in the following investor
conferences in September 2023:
Citi’s 18th Annual Biopharma ConferenceSeptember 5th-7thBoston,
MA
Wells Fargo’s 2023 Healthcare ConferenceSeptember 5th-8thBoston,
MA
Portfolio managers and analysts who would like to request a
meeting with management should contact their representative at the
respective hosting firms.
About Sensei Biotherapeutics Sensei
Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology
company focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb™ (Tumor
Microenvironment Activated biologics) platform, Sensei develops
conditionally active therapeutics designed to disable
immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells
against tumors. Sensei’s lead investigational candidate is SNS-101,
a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively
within the low pH tumor microenvironment, where VISTA acts as a
suppressor of T cells by binding the receptor PSGL-1. The company
is also developing SNS-102, a conditional binding monoclonal
antibody targeting V-Set and Immunoglobulin Domain Containing 4
(VSIG-4), as well as SNS-103, also a conditionally active
monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more
information, please visit www.senseibio.com, and follow the company
on Twitter @SenseiBio and LinkedIn.
Investor Contact:Michael
BiegaSenior Director, Investor RelationsSensei
Biotherapeuticsmbiega@senseibio.com
Media Contact:Chris RaileyTen
Bridge Communicationschris@tenbridgecommunications.com
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Sensei Biotherapeutics (NASDAQ:SNSE)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024